Introducing a New Series: Immunotherapy Facts and Hopes
Melero I (1,2), Sznol M (3), Tessmer MS (4), Whiteside TL (5), Wolchok JD (6).
The field of cancer immunotherapy is no longer in its infancy. Two lines of progress in clinical research are achieving true clinical success: (i) checkpoint blockade for solid tumors and (ii) chimeric antigen receptor (CAR) T-cell therapy for lymphoid malignancies (1).
Clinical Cancer Research (CCR) remains highly committed to publishing the best quality original translational research in the field of cancer immunotherapy. In addition, as the team of CCR editors dedicated to immunotherapy has recently expanded, we feel a profound obligation to provide the best reviews of the literature for the ongoing education of our readership, which is composed of clinicians and translational scientists in academia and industry.
Rapid innovation and progress certainly generate excitement, but they also require that advances in immunotherapy be promptly and efficiently incorporated into clinical practice.
This integration requires the rapid transfer of newly gained knowledge to practicing physicians and translational researchers and an obligation to provide ongoing updates.
To address these educational needs in the field of cancer immunotherapy, CCR has organized the publication of several review articles, including our new “Facts and Hopes” series. Written by colleagues with expertise in immunotherapy, these reviews represent authoritative, up-to-date, comprehensive presentations designed to explain the benefits of immune-based therapies.
We have made a special effort to present the material in a didactic, informative, and accessible style.
CITATION Clin Cancer Res. 2018 Feb 23. doi: 10.1158/1078-0432.CCR-18-0408